Projects per year
Personal profile
Biography
Dr. Kern is a urologic oncologist in the Murtha Cancer Center at the Uniformed Services University and Walter Reed National Military Medical Center. He is the founding Director of the Testicular cancer Enterprise for Survivorship, Treatment, and Investigational Sciences “TESTIS” Program at the Murtha Cancer Center, USU. He is also the Program Director of the National Capital Consortium Walter Reed Urology Residency. Prior to completing an advanced fellowship in Urologic Oncology at Indiana University, Dr. Kern was a staff urologist , Urology Service Chief, and Director of Surgical Quality at Fort Belvoir Community Hospital (renamed Alexander T. Augusta Military Medical Center) Fort Belvoir, VA, for four years. Dr. Kern's research interests are focused on the genetics of germ cell testicular cancer, surgical treatment and management of chemotherapy-resistant testicular cancer, and survivorship. He is also interested in the surgical treatment and quality of life aspects of bladder and prostate cancer. He is board certified by the American Board of Urology and a member of the Society of Urologic Oncology, American Urological Association, and Society of Government Service Urologists. Dr Kern is a member of the Board of Directors for the Testicular Cancer Awareness Foundation.
Research interests
Education/Academic qualification
Urologic Oncology, Indiana University
1 Jul 2019 → 28 Jun 2021
Medical Doctor, Uniformed Services University, School of Medicine
1 Jul 2005 → 28 May 2009
Biology, Bachelor, United States Air Force Academy
1 Jun 2001 → 1 Jun 2005
External positions
Member, Board of Directors, Testicular Cancer Awareness Foundation
1 Aug 2023 → 1 Aug 2029
Director, Testicular cancer Enterprise for Survivorship, Treatment, and Investigational Sciences TESTIS Program, Murtha Cancer Center, Uniformed Services University-Walter Reed
1 Sep 2022 → 13 Mar 2031
Residency Program Director, National Capital Consortium
1 Jan 2022 → 1 Jan 2028
NCR Product Line Chair, Urology, National Capital Region
1 Oct 2021 → 1 Oct 2027
Keywords
- RD Surgery
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Projects
- 1 Active
-
mi RNA 371a-3p tests for screening and diagnosis of testicular cancer
Kern, S., Bagrodia, A. & Speir, R. W.
1/09/23 → 1/09/26
Project: Research
-
Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for seminoma: Limitations of surgical intervention after first-line chemotherapy
Tachibana, I., Alabd, A., Whaley, R. D., McFadden, J., Piroozi, A., Hassoun, R., Kern, S. Q., King, J., Adra, N., Rice, K. R., Foster, R. S., Einhorn, L. H., Cary, C. & Masterson, T. A., Sep 2023, In: Urologic Oncology: Seminars and Original Investigations. 41, 9, p. 394.e1-394.e6Research output: Contribution to journal › Article › peer-review
-
Primary Retroperitoneal Lymph Node Dissection for Stage II Seminoma: Is Surgery the New Path Forward?
Tachibana, I., Alabd, A., Tong, Y., Piroozi, A., Mahmoud, M., Kern, S. Q., Masterson, T. A., Adra, N., Foster, R. S., Hanna, N. H., Einhorn, L. H. & Cary, C., 10 Aug 2023, In: Journal of Clinical Oncology. 41, 23, p. 3930-3938 9 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Isamu Tachibana, Sean Q. Kern, Antoin Douglawi, et al. Primary Retroperitoneal Lymph Node Dissection for Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumor—N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00118: Is Retroperitoneal Lymph Node Dissection Without Adjuvant Chemotherapy Enough for All Patients with Pathologic Stage II Nonseminoma Germ Cell Tumor?
Tachibana, I., Kern, S. Q., Douglawi, A., Tong, Y., Mahmoud, M., Masterson, T. A., Adra, N., Foster, R. S., Einhorn, L. H. & Cary, C., Jan 2023, In: European Urology. 83, 1, p. e20-e21Research output: Contribution to journal › Letter › peer-review
Open Access -
Can Retroperitoneal Lymph Node Dissection (RPLND) be feasibly performed to prolong survival in Renal Cell Carcinoma (RCC) with limited lymph node involvement? An Analysis of Recurrence Patterns
Tachibana, I., Vasquez, R., Mahmoud, M., Kern, S. Q., Patel, R. S., King, J., Adra, N., Boris, R. S., Cary, C. & Rice, K. R., Nov 2022, In: Urologic Oncology: Seminars and Original Investigations. 40, 11, p. 495.e11-495.e17Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Early and Midterm Complications of the Continent Catheterizable Indiana Pouch Urinary Diversion: A 7-year Experience
Burns, R., Speir, R., Kern, S. Q., Jarvis, H., Schmidt, J., Cary, C., Masterson, T., Gardner, T., Bihrle, R., Koch, M. & Kaimakliotis, H., Sep 2022, In: Urology. 167, p. 229-233 5 p.Research output: Contribution to journal › Article › peer-review
Press/Media
-
Army Strong: A Prostate Cancer Survivor’s Remarkable Road to Recovery
20/09/23 → 16/10/23
2 items of Media coverage
Press/Media